A trade group for pharmacies is pushing back on
calls for more federal regulations after a “60 Minutes”
report on a deadly fungal meningitis outbreak.
The National Community Pharmacists Association (NCPA) on Monday said there
are already “adequate” regulations in place to protect consumers who visit
small-batch pharmacies that mix custom prescriptions. The group said the New England Compounding Center (NECC), which manufactured hundreds of injectable pain medications contaminated with fungal meningitis, is a “rogue entity.” B. Douglas Hoey, the chief executive of the NCPA, said the company passed itself off as a compound pharmacy while producing drugs en masse.
“As a country, we must strike the right balance to go after rogue entities like NECC while preserving patients’ access to the safe and essential compounded medications that their physicians prescribe,” Hoey said, pledging that the organization would “continue to work with health officials” on the issue.
“NECC was in fact evading necessary regulation in part by purporting to be a compounding pharmacy,” he said.
Last fall, people that received steroid injections from the New England Compounding Center began to get sick with fungal meningitis and die. Investigations have since shown that the compound pharmacy was producing products too quickly, with one employee telling 60 Minutes that the company “got greedy” and eventually began to overlook cleanliness as more orders came in.
Hoey says that compound pharmacies – which mix custom versions of drugs for patients and require a single prescription – have adequate state and federal level protections in place.
Since compounding pharmacies can manufacture a single, specific FDA-approved medication liquid for someone unable to take pills, or flavor a child’s prescription to make it more palatable, the FDA does not have oversight of these facilities. The “60 Minutes” report concludes that this leaves the $2 billion industry to state regulators.
FDA Commissioner Margaret Hamburg told “60 Minutes” that she does not know the number of compound pharmacies in the country, or how many drugs they manufacture. But she said a lack of federal oversight will ultimately result in more deaths in the future.
But Hoey noted that the FDA “has endorsed compounding pharmacies’ role in alleviating drug shortages.”
“Without these providers, many thousands of patients would not have access to these medications and parts of the U.S. health care system would come to a standstill," he said.
Read more: http://thehill.com/blogs/regwatch/healthcare/287441-pharmacies-push-back-on-call-for-regulations-after-60-minutes-report#ixzz2NHKCFL2W
Follow us: @thehill on Twitter | TheHill on Facebook